Format

Send to

Choose Destination
Cancer Sci. 2016 Oct;107(10):1484-1491. doi: 10.1111/cas.13025. Epub 2016 Sep 2.

Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki.

Author information

1
Department of Hematology, Atomic Bomb Disease and Hibakusya Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
2
Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
3
Department of Frontier Life Science, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. masakoiwng@nagasaki-u.ac.jp.
4
Division of Scientific Data Registry, Atomic Bomb Disease and Hibakusya Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
5
Nagasaki Prefectural Cancer Registry, Nagasaki, Japan.
6
Department of Epidemiology, Radiation Effects Research Foundation, Nagasaki, Japan.
7
Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
8
Department of Internal Medicine, St. Francis Hospital, Nagasaki, Japan.
9
Department of Internal Medicine, Nagasaki Harbor Medical Center City Hospital, Nagasaki, Japan.
10
Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
11
Department of Hematology, Atomic Bomb Disease and Hibakusya Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan. y-miyaza@nagasaki-u.ac.jp.
12
Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. y-miyaza@nagasaki-u.ac.jp.
13
Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan. y-miyaza@nagasaki-u.ac.jp.

Abstract

There is evidence that radiation exposure is a causative factor of myelodysplastic syndromes (MDS). However, little is known about whether radiation exposure is also a prognostic factor of MDS. We investigated the impact of radiation exposure on the prognosis of MDS in Nagasaki atomic bomb survivors using the International Prognostic Scoring System (IPSS) and the revised version (IPSS-R). Subjects were 140 patients with primary MDS diagnosed between 1985 and 2011 and evaluable for IPSS, IPSS-R, and exposure distance. Of those, 31 were exposed at <1.5 km, 35 at 1.5-2.99 km, and 74 at ≥3.0 km. By the end of March 2014, 47 patients (34%) progressed to overt leukemia and 106 (75.7%) died. By comparing with patients exposed at ≥3.0 km, those exposed at <1.5 km had significantly higher frequencies of abnormal chromosome (P = 0.02), intermediate/poor IPSS, and intermediate/poor/very poor IPSS-R cytogenetic category (P = 0.0001, and P < 0.0001, respectively). As with de novo MDS, multivariate Cox regression analyses revealed that cytogenetic abnormalities, IPSS karyotype, and IPSS-R cytogenetics were significantly associated with poor survival, and cumulative incidence of leukemic transformation in MDS among atomic bomb survivors, but exposure distance was not associated with any poor outcomes. These suggest that exposure to the greater dose of atomic bomb radiation is associated with developing poor cytogenetic abnormalities in MDS, which might consequently lead to overt leukemia among atomic bomb survivors.

KEYWORDS:

Atomic bomb survivors; myelodysplastic syndromes; prognosis; radiation exposure; therapy-related myeloid neoplasms

PMID:
27487572
PMCID:
PMC5084675
DOI:
10.1111/cas.13025
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center